Form 4: Agenus Director Timothy Wright Granted Stock Options Following Shareholder Approval

Agenus Inc. director Timothy Wright was granted 15,750 stock options with an exercise price of $3.02 per share, following shareholder approval obtained on June 17, 2025.

Summary

• Timothy Wright, a Director of Agenus Inc. (AGEN), was granted a total of 15,750 stock options.
• The options have an exercise price of $3.02 per share and an expiration date of May 28, 2035.
• The grants were made on May 28, 2025, contingent on shareholder approval, which was secured at the company's annual meeting on June 17, 2025.
• One portion of the grant, for 750 shares, vests over three years, with one-third vesting on May 28, 2026, and the remainder in equal quarterly installments thereafter.
• The second, larger portion of the grant, for 15,000 shares, vests entirely on the one-year anniversary of the grant date, May 28, 2026.
• These options were awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The document reports a standard grant of stock options to a director, which is a common practice to align management interests with shareholder value. It reflects routine corporate governance and compensation, without indicating any significant positive or negative operational or financial news.

Positives

• The grant of stock options aligns the interests of Director Timothy Wright with those of shareholders, incentivizing long-term company performance.
• The options were granted under an existing, shareholder-approved equity incentive plan (Agenus Inc. 2019 Amended and Restated Equity Incentive Plan), indicating standard corporate governance practices.
• Shareholder approval for the options was obtained, demonstrating transparency and adherence to governance requirements.

Future Outlook

This document does not provide a future outlook for the company's performance or strategy. It solely reports an insider transaction.

Industry Context

The granting of stock options to directors is a common practice across various industries, including biotechnology, to incentivize long-term commitment and align interests with shareholders. This filing reflects a standard compensation mechanism within the corporate governance framework.

Comparison to Industry Standards

• The grant of stock options to a director is a standard practice for executive and director compensation in publicly traded companies, particularly in the biotechnology sector like Agenus Inc.
• The vesting schedules (one-third annually over three years, and a one-year cliff vest) are common structures designed to retain talent and align long-term interests.
• The use of a shareholder-approved equity incentive plan (Agenus Inc. 2019 Amended and Restated Equity Incentive Plan) is also standard for ensuring proper governance and transparency in compensation practices.
• Specific comparable companies or projects are not mentioned in the document, but this type of compensation structure is widely observed across the biotech and pharmaceutical industries for non-employee directors.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align their interests with shareholders, potentially leading to better long-term performance. However, it also represents potential future dilution if options are exercised.

Next Steps

• The vesting of the 750-share option grant will continue in equal quarterly installments after May 28, 2026, until fully vested.
• The 15,000-share option grant will fully vest on May 28, 2026.

Key Dates

Keywords

Agenus Inc., AGEN, SEC Form 4, Stock Options, Insider Transaction, Director Compensation, Equity Incentive Plan, Timothy Wright, Shareholder Approval